VENLO, Netherlands and KOLKATA, India, April 21 /PRNewswire-Asia/ --
QIAGEN and the Chittaranjan National Cancer Institute (CNCI) today announced a
collaboration to establish the first large-scale cervical cancer screening
program for women in Kolkata, India. QIAGEN (Nasdaq: QGEN; Frankfurt Prime
Standard: QIA) will provide its diagnostic tests for the human papillomavirus
(HPV) -- the primary cause of cervical cancer. CNCI will conduct the screening
and provide appropriate treatment as needed.

The "QIAGENcares Kolkata Project" will use QIAGEN's hybrid capture 2 (hc2)
HPV DNA testing technology (also known as the digene(R) HPV Test) to screen
women for cancer-causing types of HPV to identify those with or at risk for
developing cervical cancer. Participating women will also be screened using
VIA (visual inspection with acetic acid) as per the Indian National Guidelines
for Cervical Screening. Screening will take place at community-based mobile
field clinics in the villages neighboring Kolkata. Women found to have
cervical cancer or pre-cancer will be immediately treated at the field clinic
-- a process referred to as "screen and treat" -- or referred to the CNCI for
follow up. The project also includes educational campaigns to raise awareness
about HPV, cervical cancer, and other women's health issues. The initiative
will be conducted over 5 years and is expected to reach 50,000 women.

Despite being a preventable cancer with a known primary cause, cervical
cancer claims nearly 300,000 lives every year -- with 80% of these deaths
occurring in developing countries. India has more cervical cancer cases than
any other country in the world. The World Health Organization (WHO) estimates
that every year more than 130,000 Indian women are diagnosed with cervical
cancer and more than 74,000 die from it. This makes cervical cancer the
leading cause of cancer related deaths in India and represents approximately
1/4 of the world's total cervical cancer cases and mortality. The WHO
estimates that only about 5 percent of women in the developing world have been
screened for cervical disease in the previous five years, compared to 40-50
percent in the developed world.

"This project is a great demonstration of how our advanced screening
solutions can bring state of the art healthcare to women in all regions of the
globe. Kolkata, India is a particularly fitting location to launch this
project as India has the world's highest incidence rate of cervical cancer. We
believe that launching this project can play a role in helping to change those
statistics," said Mr. Peer Schatz, CEO of QIAGEN. "Through the QIAGENcares
Kolkata collaboration we will increase awareness about cervical cancer
prevention and make screening more accessible, two vital ingredients in the
effort to reduce cervical cancer rates. Also, we are looking forward to
demonstrating the combination of cost effectiveness and enormous value for
healthcare that QIAGEN's state of the art cervical cancer screening solutions
can bring to a setting such as the one in Kolkata." The Kolkata screening
project is a part of QIAGENcares, the company's corporate social
responsibility program focused on improving health by providing access to
screening methods for infectious diseases in emerging and developing countries.

"We are pleased to work with QIAGEN on this cervical cancer screening
project. We here at the CNCI see first-hand how serious a threat cervical
cancer is to the health of women locally and to Indian society as a whole. We
hope this collaboration will help raise awareness of the issue and set an
example for other screening projects in the future," said Dr. Jaydip Biswas,
Director, CNCI.

The cervical cancer screening program will be officially launched at the
opening ceremony of the 2009 Asia-Oceania Research Organization on Genital
Infections and Neoplasia (AOGIN) conference in Kolkata on April 25-26. The
first women are expected to be screened in June.

The impact of HPV testing on cervical cancer incidence and death in India
was demonstrated in an International Agency for Research on Cancer (IARC)
study published in the April 2, 2009 issue of the New England Journal of
Medicine. The trial evaluated cervical cancer prevention tools in 130,000
women in the Maharashtra state of India, and found HPV testing to be the most
effective way to reduce cervical cancer incidence when compared to either Pap
(cytology) testing or VIA. The study demonstrated that a single round of HPV
testing was associated with a significant reduction in the numbers of advanced
cervical cancers and deaths.

QIAGEN's HPV test platform -- known as the digene HPV Test -- uses
advanced molecular diagnostic technologies to identify the presence of the
genetic code (DNA) of 13 high-risk, cancer-causing types of HPV. The digene
HPV Test has been published in more than 300 peer-reviewed journal articles
and studied in clinical trials involving more than 825,000 women worldwide.
More than 40 million tests for carcinogenic HPV have been performed with the
digene HPV Test, which is recognized as the "gold-standard" in HPV testing.

About QIAGEN:

QIAGEN N.V., a Netherlands holding company, is the leading global provider
of sample and assay technologies. Sample technologies are used to isolate and
process DNA, RNA and proteins from biological samples such as blood or tissue.
Assay technologies are used to make such isolated biomolecules visible. QIAGEN
has developed and markets more than 500 consumable products as well as
automated solutions for such consumables. The company provides its products to
molecular diagnostics laboratories, academic researchers, pharmaceutical and
biotechnology companies, and applied testing customers for purposes such as
forensics, animal or food testing and pharmaceutical process control. QIAGEN's
assay technologies include one of the broadest panels of molecular diagnostic
tests available worldwide. This panel includes the digene HPV Test, which is
regarded as the "gold standard" in testing for high-risk types of human
papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs
more than 3,000 people in over 30 locations worldwide. Further information
about QIAGEN can be found at http://www.qiagen.com/ .

About the CNCI:

The Chittaranjan National Cancer Institute (CNCI) was established by Prof.
Subodh Mitra, a gynecological oncologist and inaugurated by Noble Laureate
Madam Irene Curie on 12th January, 1950. It is an autonomous Institution
under the Ministry of Health & Family Welfare, Government of India and jointly
financed by the Government of India and the Government of West Bengal. The
CNCI continues to uphold its original commitments to the control and
prevention of human cancer. The 200 bed hospital facility caters to more than
6,500 new cancer patients originating from different states of Eastern India
as well as from Bangladesh and Nepal. The CNCI places a strong emphasis on
projects for community oriented early cancer detection and promotion of cancer
awareness.

Statements contained in this release that are not historical facts are
forward-looking statements, including statements about our products, markets,
strategy and operating results. Such statements are based on current
expectations that involve risks and uncertainties including, but not limited
to, those associated with: management of growth and international operations
(including currency fluctuations and logistics), variability of our operating
results, commercial development of our markets (including applied testing,
clinical and academic research, proteomics, women's health/HPV testing and
molecular diagnostics), our relationships with customers, suppliers and
strategic partners, competition, changes in technology, fluctuations in demand,
regulatory requirements, identifying, developing and producing integrated
products differentiated from our competitors' products, market acceptance of
our products, and integration of acquired technologies and businesses. For
further information, refer to our filings with the SEC, including our latest
Form 20-F. Information in this release is as of the date of the release, and
we undertake no duty to update this information unless required by law.

(Date:12/9/2016)... York , December 9, 2016 ... that the top five players in the Global Label-Free ... in the overall market in 2015. Players such as ... Elmer have remained dominant in the global market due ... to ensure product innovation. Product upgrades and timely product ...

(Date:11/21/2016)... , Nov. 21, 2016 Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...